AstraZeneca And Oracle Form AI Pact To Improve Clinical Trial Recruitment
The Catalyst Brief
Coverage
AI in Drug Discovery
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Latest
Lilly Signs Up To $1.1 Billion Metis Deal, Extending Its AI-Enabled Delivery Push
The Catalyst Brief
AstraZeneca Commits Up To $1.5 Billion To Insitro For AI-Led MASH And Cardiomyopathy Target Discovery
The Catalyst Brief
Zealand Pharma Adds Up To $1.2 Billion Generate Alliance, Broadening Its Obesity Modalities After Mixed Readouts
The Catalyst Brief
Most read
Xaira Reveals XA-1 And XA-4, Framing X-Design As A Drug-Ready Antibody Engine
The Catalyst Brief
AI-Centric Biotechs Draw Billion-Dollar Backing, Pressuring Biopharma To Move Risk Checks Upstream
The Catalyst Brief
Biopharma R&D Needs 'Structural Redesign' to Maximize AI Impact, Says McKinsey
The Catalyst Brief
Deep Learning Perturbation Models Beat Uninformative Baselines Under Calibrated Metrics, Nature Study Finds
The Catalyst Brief
More in this beat
Oct 9, 2026GSK Signs Chai Discovery After Wet-Lab Binders Across Tested Targets
Chai said its models generated designs to GSK targets zero-shot, without target-specific training. For AI drug discovery, the signal in this deal is not a revenue number but the kind of validation that can move a platform from attention-grabbing preprints toward broader use inside pharma research organizations.
The Catalyst Brief
Oct 8, 2026Iambic Targets $135 Million IPO, Extending 2026 Biotech Listing Momentum
Iambic plans to offer 9.4 million shares at $15 to $17 each, a range that implies about $150 million in gross proceeds and approximately $135 million after expenses. The company said it would direct the money primarily to IAM1363, while also moving IAM217 and IAM-C1 forward and continuing to invest in its Enchant and NeuralPLexer models.
The Catalyst Brief
Oct 3, 2026Xaira Reveals XA-1 And XA-4, Framing X-Design As A Drug-Ready Antibody Engine
Xaira said XA-1, a cancer candidate, was created from scratch in seven weeks, while XA-4 targets a G-protein coupled receptor the company described as seemingly intractable to antibody approaches. The announcement offers the clearest sign yet that the company is trying to differentiate its AI platform on developability, not just binding hits.
The Catalyst Brief
Oct 1, 2026Deep Learning Perturbation Models Beat Uninformative Baselines Under Calibrated Metrics, Nature Study Finds
The paper targets a core credibility problem in AI-based perturbation modeling: whether these systems capture perturbation-specific biology or just exploit weak benchmarks. Its answer is not that every model works, but that benchmark design can obscure real signal and distort where the field directs research effort.
The Catalyst Brief
Sep 25, 2026Genentech Pays $55 Million Upfront In Earendil Bispecific Deal, Extending Roche’s Oncology Search
Earendil will handle antibody discovery and early clinical research on pre-agreed oncology target combinations before Genentech takes over global clinical development and commercialization. The pact shows how AI-enabled antibody design platforms are still winning large, backloaded licensing structures when large drugmakers want faster access to bispecific optionality rather than a single disclosed asset.
The Catalyst Brief
Sep 25, 2026Basecamp Research Raises $140 Million Series C, Extending Investor Appetite For AI-Designed Drug Platforms
The London- and Boston-based company said the oversubscribed round was led by S32 and included NVIDIA, Anthropic and senior biopharma leaders including Roche Vice Chairman André Hoffmann. Basecamp plans to use the financing to move investigational medicines forward, initially focusing on in vivo cell therapies.
The Catalyst Brief
Sep 24, 2026Boehringer Ingelheim Expands Variant Bio Pact Beyond Kidney Disease, Adding More Than $250M In Cardiovascular Economics
The companies are pairing Variant Bio's genomics and multiomic discovery platform with Boehringer's cardiovascular and kidney disease expertise. The commercial signal is that pharmas are continuing to spend on genetically supported target discovery in large chronic diseases, where better target validation can matter more than novelty alone.
The Catalyst Brief
Sep 22, 2026Boehringer Ingelheim Signs Potential $1 Billion Envisagenics Oncology Pact, Expanding RNA-Splicing Target Hunt
Boehringer Ingelheim is betting that alternative RNA splicing can open a less crowded oncology target space, while Envisagenics is using the economics of platform partnering to fund its internal pipeline. The structure shows how AI target-discovery companies are increasingly trying to convert discovery collaborations into financing for wholly owned programs.
The Catalyst Brief
Sep 22, 2026Deep Dive: AI Becomes Core Biopharma Infrastructure, From Pfizer Integration To TechBio Funding
Pharma executives are increasingly describing AI as a structural capability rather than an experimental add-on. At the same time, companies built around machine learning platforms are drawing large partnerships and financing rounds, creating a clearer commercial divide between established use cases and earlier-stage platform promise.
The Catalyst Brief
Sep 9, 2026Forus Secures $150 Million Series C At $3 Billion Valuation, Expanding AI Medication Access Network
Formerly known as Tandem, Forus connects doctors, pharmacies, payers and biopharma and uses AI agents to navigate insurance, financial assistance and pharmacy logistics for prescribed medicines. The new financing will fund more AI agents and clinical models, broader specialty coverage and expansion of the company’s technical and go-to-market teams.
The Catalyst Brief
Aug 27, 2026Generate Biomedicines’ GB-0895 Posters Leak Two Weeks Early, Exposing New Phase 1 COPD And Asthma Data
According to an SEC filing, draft copies of three posters were made publicly available via the ERS website on Aug. 25, nearly two weeks before the Sept. 7 embargo expired. The episode gave investors an early look at ongoing clinical data for golukibart, two days before a scheduled lock-up expiry reshaped the share register.
The Catalyst Brief
Aug 27, 2026Flagship’s ProFound Signs Up To $35 Million Gates Foundation Pact For Preeclampsia Targets
Flagship Pioneering’s ProFound Therapeutics has partnered with the Gates Foundation in a pact worth up to $35 million focused on preeclampsia, a high-blood-pressure disease of pregnancy that can be fatal for mother or child if not addressed. The collaboration pairs ProFound’s proteomics repository with an agentic AI tool meant to help assign function to newly identified targets before laboratory validation.
The Catalyst Brief
Other beats
Biopharmaceutical Industry
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Biotech Innovation
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Healthcare Investment
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Medical Technology
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
Regulatory & Policy
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.